Integration of Clinical Pharmacokinetic Database With Compartmental Modeling and Regulatory Data Analysis

Area of Science:

• Pharmacometrics
• Clinical Pharmacology
• Drug Development

Background:

• Computational pharmacokinetics is shifting towards real-world clinical data over theoretical simulations.
• This study integrated patient measurements from PK-DB clinical trials with FDA regulatory databases.
• The goal was to characterize drug disposition patterns using authentic clinical data.

Purpose of the Study:

• To analyze drug disposition patterns for caffeine and paracetamol using real-world patient data.
• To validate a modeling framework for deriving interpretable pharmacokinetic parameters.
• To establish a foundation for evidence-based dose optimization in translational pharmacometrics.

Main Methods:

• Analyzed concentration-time profiles from 75 patients receiving caffeine or paracetamol.
• Employed noncompartmental and one-compartment modeling approaches.
• Utilized nonlinear least squares optimization of actual clinical measurements and FDA regulatory API queries.

Main Results:

• Caffeine showed dose-linear kinetics (t½ 4.0 h, CL 2.96 L/h).
• Paracetamol exhibited faster elimination (t½ 1.8 h, CL 14.29 L/h).
• One-compartment models demonstrated excellent fit (R² > 0.98), validating the approach against published data.

Conclusions:

• Curated clinical databases and empirical modeling yield interpretable pharmacokinetic parameters from actual measurements.
• This framework supports evidence-based dose optimization for over 150 compounds in PK-DB.
• The approach offers significant advantages over simulation-dependent methodologies in translational pharmacometrics.